Print Page  Close Window     


SEC Filings


8-K
VANDA PHARMACEUTICALS INC. filed this Form 8-K on 11/07/2018
Entire Document
 << Previous Page | Next Page >>


VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for share and per share amounts)

(unaudited)

 

     Three Months Ended      Nine Months Ended  
     September 30
2018
     September 30
2017
     September 30
2018
     September 30
2017
 

Revenues:

           

HETLIOZ® product sales, net

   $ 29,923      $ 22,279      $ 83,391      $ 64,968  

Fanapt® product sales, net

     19,212        19,057        56,686        55,839  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

     49,135        41,336        140,077        120,807  

Operating expenses:

           

Cost of goods sold excluding amortization

     5,068        4,525        14,841        13,057  

Research and development

     11,390        10,178        30,672        28,393  

Selling, general and administrative

     26,047        31,124        80,829        92,792  

Intangible asset amortization

     397        432        1,147        1,318  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

     42,902        46,259        127,489        135,560  
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) from operations

     6,233        (4,923      12,588        (14,753

Other income

     1,030        396        2,440        1,073  
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     7,263        (4,527      15,028        (13,680

Provision for income taxes

     92        23        180        49  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income (loss)

   $ 7,171      $ (4,550    $ 14,848      $ (13,729
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income (loss) per share, basic

   $ 0.14      $ (0.10    $ 0.30      $ (0.31

Net income (loss) per share, diluted

   $ 0.13      $ (0.10    $ 0.28      $ (0.31

Weighted average shares outstanding, basic

     52,389,012        44,885,287        50,321,640        44,669,201  

Weighted average shares outstanding, diluted

     54,709,749        44,885,287        52,315,642        44,669,201  

 

Page 5 of 7

 << Previous Page | Next Page >>